Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19056526 | 0.92 | ABCB1 (0.49) | MEN1KMT2ANPSR1SYKCTSL | |
| SCHEMBL25762545 | 0.86 | SYK (0.48) | SYKPDK1PDK2PDK3PDK4 | |
| SCHEMBL30452094 | 0.86 | MEN1 (0.45) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL18988819 | 0.85 | MEN1 (0.49) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL30511007 | 0.85 | OPRD1 (0.49) | KMT2ANPSR1SYKCTSL | |
| SCHEMBL30567879 | 0.84 | TSHR (0.43) | MEN1KMT2APDK1CTSLDRD2 | |
| SCHEMBL12496208 | 0.84 | FKBP1A (0.52) | SYKTMEM97SIGMAR1CTSL | |
| SCHEMBL18989117 | 0.83 | ABCB1 (0.48) | MEN1KMT2ANPSR1SYKABCB1 | |
| SCHEMBL18150052 | 0.83 | PARP1 (0.55) | MEN1KMT2ASYKSIGMAR1PDK1 | |
| SCHEMBL31509786 | 0.82 | MEN1 (0.45) | MEN1KMT2ANPSR1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4440700-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12084467-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023102529-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084467-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | MEN1 4418/4885KMT2A 3782/4885NPSR1 4454/4885 |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | MEN1 4418/4885KMT2A 3782/4885NPSR1 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.